Spero Therapeutics Inc
F:2HA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Spero Therapeutics Inc
F:2HA
|
US |
|
V
|
Vertex Pharmaceuticals Inc
F:VX1
|
US |
Intrinsic Value
The intrinsic value of 
Spero Therapeutics Inc (2HA) under the Base Case is 0.7701 EUR per share.
Compared with the current market price of 0.9065 EUR, the stock appears
Overvalued by 15% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Spero Therapeutics Does
Spero Therapeutics is a biotechnology company that develops medicines for hard-to-treat bacterial infections, with a focus on infections caused by drug-resistant Gram-negative bacteria. Its work centers on antibiotic candidates designed to be taken by mouth or given in other convenient ways, so they can treat serious infections that often require hospital care.
- Headquarters
- United States of America US
- Employees
- 25
- IPO date
- Nov 2, 2017
Revenue & Expenses Breakdown
Spero Therapeutics Inc
Earnings Waterfall
Spero Therapeutics Inc
The intrinsic value for Spero Therapeutics Inc (2HA) under the Base Case is 0.7701 EUR.
Compared with the current market price of 0.9065 EUR, the stock appears Overvalued by 15% .
